Showing 2071-2080 of 4063 results for "".
- Tarsus Pharmaceuticals Appoints Wendy Yarno to Board of Directorshttps://modernod.com/news/tarsus-pharmaceuticals-appoints-wendy-yarno-to-board-of-directors/2478584/Tarsus Pharmaceuticals announced the appointment of Wendy L. Yarno to its Board of Directors and its audit committee. Ms. Yarno has more than 30 years of experience in the biopharmaceutical industry, as a public company director and product commercialization leader, including 26 years at Merck &a
- FDA Accepts Santen’s NDA for Cyclosporine Topical Ophthalmic Emulsion for the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18https://modernod.com/news/fda-accepts-santens-nda-for-cyclosporine-topical-ophthalmic-emulsion-for-the-treatment-of-severe-vernal-keratoconjunctivitis-in-patients-ages-4-18/2478457/Santen announced that the FDA has accepted the new drug application (NDA) for cyclosporine topical ophthalmic emulsion 0.1% for the treatment of severe vernal keratoconjunctivitis (VKC) in patients ages 4-18. The FDA has set June 26, 2021 as the Prescription Drug Use
- Pioneering Ophthalmologist Spencer P. Thornton, MD, Dies at Age 90https://modernod.com/news/pioneering-ophthalmologist-spencer-p-thornton-md-dies-at-age-90/2477074/Spencer P. Thornton, MD, died at age 90 on October 26, 2019. A pioneer in the field of refractive surgery, Dr. Thornton served as the president of the ASCRS from 1997 to 1999 and received the society’s lifetime achievement award earlier this year. He was an internationally recognized speaker and
- Alcon Showcases New Vitrectomy Probe and Next Generation Ngenuity 3D Visualization System at ASRShttps://modernod.com/news/alcon-showcases-new-vitrectomy-probe-and-nextgeneration-ngenuity-3d-visualization-system-at-asrs/2476772/Alcon is introducing the Hypervit Dual Blade Vitrectomy Probe, the newest addition to the Constellation Vision System, at the American Society of Retina Specialists (ASRS) 2019 annual meeting taking place July 26-30 in Chicago. The company is also featuring its next generation Ngenuity 3D Visuali
- Clearside Biomedical Announces Multiple Oral Presentations to be Given at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-oral-presentations-to-be-given-at-the-asrs-annual-meeting/2476742/Clearside Biomedical announced that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space will be given at the upcoming American Society of Retinal Specialists (ASRS) annual meeting taking place July 26-30, 2019 in Chicago. <
- Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During ASCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/Bausch + Lomb announced that 26 new scientific analyses, including 23 podium presentations and three posters, will feature the company’s surgical and pharmaceutical products during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- FDA Accepts Eluminex Biosciences' IND Application for Trispecific Fusion Antibody for DMEhttps://modernod.com/news/fda-accepts-eluminex-biosciences-ind-application-for-trispecific-fusion-antibody-for-dme/2482259/Eluminex Biosciences announced the acceptance of its EB-105 IND application to the FDA. EB-105 is a novel trispecific fusion antibody targeting VEGF-A (and isomers), VEGF-B, placental growth factor (PlGF), angiopoetin-2 (Ang-2), and interleukin-6 receptor (IL-6R) for the treatment of DM
- NIAID Launches ACTT 2 Trial Testing Gilead’s Remdesivir Plus Eli Lilly, Incyte’s JAK Inhibitor Olumiant in COVID-19https://modernod.com/news/niaid-launches-actt-2-trial-testing-gileads-remdesivir-plus-eli-lilly-incytes-jak-inhibitor-olumiant-in-covid-19/2477741/The US National Institute of Allergy and Infectious Diseases (NIAID) said Friday that it is enrolling hospitalized adults with COVID-19 in the US to take part in a study evaluating the combination of Gilead Sciences’ remdesivir with Eli Lilly and Incyte’s JAK inhibitor Olumiant as a p
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem